Phase 2 Trial of Inhaled Therapy Aviptadil OK’d in Germany

Phase 2 Trial of Inhaled Therapy Aviptadil OK’d in Germany

305683

Phase 2 Trial of Inhaled Therapy Aviptadil OK’d in Germany

A Phase 2 clinical trial investigating the inhaled sarcoidosis therapy aviptadil — also known as RLF-100, and designed to block inflammation in the lungs — has been cleared to start in Germany. The clearance by the German medical regulatory authority Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) was given to AdVita Lifescience, the original developer of aviptadil, which was recently acquired by Relief Therapeutics. “Receiving regulatory clearance to begin a phase 2 clinical trial of inhaled aviptadil marks…

You must be logged in to read/download the full post.